Astrana Health, Inc. (NASDAQ:ASTH) Short Interest Update

Astrana Health, Inc. (NASDAQ:ASTH) saw a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,440,000 shares, a decrease of 23.0% from the February 13th total of 1,870,000 shares. Approximately 3.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 346,500 shares, the short-interest ratio is currently 4.2 days.

Astrana Health Price Performance

Shares of ASTH stock opened at $30.60 on Tuesday. Astrana Health has a 52-week low of $23.12 and a 52-week high of $63.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The firm has a market capitalization of $1.72 billion, a P/E ratio of 23.54, a P/E/G ratio of 1.37 and a beta of 1.30. The stock has a 50 day moving average price of $33.95 and a 200 day moving average price of $42.95.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The business had revenue of $665.21 million for the quarter, compared to the consensus estimate of $617.24 million. As a group, sell-side analysts predict that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Investors Weigh In On Astrana Health

A number of institutional investors and hedge funds have recently modified their holdings of ASTH. Principal Financial Group Inc. bought a new stake in shares of Astrana Health during the 3rd quarter worth approximately $13,383,000. Victory Capital Management Inc. bought a new stake in Astrana Health during the 3rd quarter valued at $2,596,000. KBC Group NV bought a new stake in Astrana Health during the 3rd quarter valued at $70,000. Royce & Associates LP bought a new stake in Astrana Health during the 3rd quarter valued at $6,661,000. Finally, Natixis Advisors LLC bought a new stake in Astrana Health during the 3rd quarter valued at $1,621,000. 52.77% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ASTH has been the subject of a number of research reports. Robert W. Baird dropped their price target on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Bank of America dropped their price target on Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Truist Financial dropped their price target on Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 13th. Stifel Nicolaus lowered their price objective on Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Finally, Macquarie raised Astrana Health to a “hold” rating in a research note on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.83.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.